| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 5 | -30,550 | 100% | $64.60 | -$1,973,421 |
| Net | -5 | -30,550 | -100% | -$1,973,421 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Conroy Kevin T. | President and CEO, Director | $150,260,323 | 27 Feb 2026 | ||
| Sarah Condella | EVP, Human Resources | $14,780,566 | 27 Feb 2026 | ||
| Brian Baranick | EVP, GM, Precision Oncology | $11,431,132 | -$200,289 | -1.7% | 25 Feb 2026 |
| Jacob A. Orville | EVP, GM, Screening | $11,174,341 | -$375,000 | -3.2% | 25 Feb 2026 |
| James Herriott | SVP, General Counsel & Sec | $7,467,489 | -$265,120 | -3.4% | 25 Feb 2026 |
| Aaron Bloomer | EVP, Chief Financial Officer | $6,751,158 | 25 Feb 2026 | ||
| Katherine S. Zanotti | Director | $3,949,335 | -$950,612 | -19% | 24 Oct 2025 |
| Everett Cunningham | Chief Commercial Officer | $3,805,686 | 30 Apr 2024 | ||
| James Edward Doyle | Director | $3,477,720 | -$182,400 | -5% | 09 Oct 2025 |
| D. Scott Coward | Director | $3,316,946 | 12 Jun 2025 | ||
| Daniel J. Levangie | Director | $1,828,143 | 12 Jun 2025 | ||
| Jeffrey Thomas Elliott | Chief Financial Officer | $1,746,571 | 30 Apr 2024 | ||
| Pierre Jacquet | Director | $1,732,836 | 08 Jun 2023 | ||
| Kathleen Sebelius | Director | $1,677,656 | 13 Jun 2024 | ||
| Shacey Petrovic | Director | $1,539,738 | 12 Jun 2025 | ||
| Freda Lewis-Hall | Director | $1,447,068 | 08 Jun 2023 | ||
| Paul J. Clancy | Director | $1,387,304 | 12 Jun 2025 | ||
| Leslie L. Trigg | Director | $914,764 | 12 Jun 2025 | ||
| Kimberly J. Popovits | Director | $872,779 | 12 Jun 2025 | ||
| Michael J. Barber | Director | $699,886 | 12 Jun 2025 | ||
| Timothy J. Scannell | Director | $418,509 | 31 Oct 2023 | ||
| Thomas D. Carey | Director | $388,962 | 02 Jun 2021 |
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Conroy Kevin T. | EXAS | Common Stock | Tax liability | -2.49% | -32,007 | 1,251,570 | 27 Feb 2026 | Direct | ||
| Conroy Kevin T. | EXAS | Common Stock | Options Exercise | 5.57% | 68,097 | 1,291,105 | 27 Feb 2026 | Direct | ||
| Conroy Kevin T. | EXAS | Restricted Stock Units | Options Exercise | -79% | -68,097 | 18,143 | 27 Feb 2026 | Direct | ||
| Sarah Condella | EXAS | Common Stock | Tax liability | -1.44% | -1,913 | 131,121 | 27 Feb 2026 | Direct | ||
| Sarah Condella | EXAS | Common Stock | Options Exercise | 3.02% | 3,900 | 133,034 | 27 Feb 2026 | Direct | ||
| Sarah Condella | EXAS | Stock Options (Right to Buy) | Options Exercise | -100% | -3,900 | 0 | 27 Feb 2026 | Direct | ||
| Sarah Condella | EXAS | Restricted Stock Units | Award | 23,224 | 23,224 | 25 Feb 2026 | Direct | |||
| James Herriott | EXAS | Restricted Stock Units | Award | 20,321 | 20,321 | 25 Feb 2026 | Direct | |||
| Conroy Kevin T. | EXAS | Common Stock | Tax liability | -0.5% | -6,196 | 1,241,955 | 25 Feb 2026 | Direct | ||
| Conroy Kevin T. | EXAS | Common Stock | Award | 1.07% | 13,181 | 1,248,151 | 25 Feb 2026 | Direct | ||
| Conroy Kevin T. | EXAS | Restricted Stock Units | Award | 154,829 | 154,829 | 25 Feb 2026 | Direct | |||
| Brian Baranick | EXAS | Restricted Stock Units | Award | 28,063 | 28,063 | 25 Feb 2026 | Direct | |||
| Jacob A. Orville | EXAS | Restricted Stock Units | Award | 38,707 | 38,707 | 25 Feb 2026 | Direct | |||
| Aaron Bloomer | EXAS | Restricted Stock Units | Award | 28,063 | 28,063 | 25 Feb 2026 | Direct | |||
| Brian Baranick | EXAS | Common Stock | Tax liability | -12.6% | -14,938 | 103,874 | 24 Dec 2025 | Direct | ||
| Brian Baranick | EXAS | Common Stock | Award | 32.9% | 29,416 | 118,812 | 24 Dec 2025 | Direct | ||
| Jacob A. Orville | EXAS | Common Stock | Award | 222.7% | 72,523 | 105,088 | 23 Dec 2025 | Direct | ||
| Jacob A. Orville | EXAS | Common Stock | Tax liability | -73% | -68,437 | 25,333 | 23 Dec 2025 | Direct | ||
| Jacob A. Orville | EXAS | Common Stock | Options Exercise | 73,080 | 69,511 | 23 Dec 2025 | Direct | |||
| Jacob A. Orville | EXAS | Restricted Stock Units | Options Exercise | -100% | -73,080 | 0 | 23 Dec 2025 | Direct | ||
| Brian Baranick | EXAS | Common Stock | Award | 167.2% | 63,107 | 100,859 | 23 Dec 2025 | Direct | ||
| Brian Baranick | EXAS | Common Stock | Tax liability | -74% | -69,159 | 24,314 | 23 Dec 2025 | Direct | ||
| Brian Baranick | EXAS | Common Stock | Options Exercise | 73,080 | 66,487 | 23 Dec 2025 | Direct | |||
| Brian Baranick | EXAS | Restricted Stock Units | Options Exercise | -100% | -73,080 | 0 | 23 Dec 2025 | Direct | ||
| Sarah Condella | EXAS | Common Stock | Award | 42.5% | 42,018 | 140,883 | 23 Dec 2025 | Direct | ||
| Sarah Condella | EXAS | Common Stock | Tax liability | -33.3% | -41,938 | 83,942 | 23 Dec 2025 | Direct | ||
| Sarah Condella | EXAS | Common Stock | Options Exercise | 66.6% | 47,208 | 118,059 | 23 Dec 2025 | Direct | ||
| Sarah Condella | EXAS | Restricted Stock Units | Options Exercise | -100% | -47,208 | 0 | 23 Dec 2025 | Direct | ||
| Conroy Kevin T. | EXAS | Common Stock | Tax liability | -25.4% | -335,549 | 986,401 | 23 Dec 2025 | Direct | ||
| Conroy Kevin T. | EXAS | Common Stock | Award | 173.8% | 713,931 | 1,124,727 | 23 Dec 2025 | Direct | ||
| James Herriott | EXAS | Common Stock | Award | 2767.7% | 72,320 | 74,933 | 23 Dec 2025 | Direct | ||
| James Herriott | EXAS | Common Stock | Tax liability | -80% | -49,870 | 12,458 | 23 Dec 2025 | Direct | ||
| James Herriott | EXAS | Common Stock | Options Exercise | 33,780 | 32,934 | 23 Dec 2025 | Direct | |||
| James Herriott | EXAS | Restricted Stock Units | Options Exercise | -100% | -33,780 | 0 | 23 Dec 2025 | Direct | ||
| Aaron Bloomer | EXAS | Common Stock | Tax liability | -44.3% | -27,954 | 35,187 | 23 Dec 2025 | Direct | ||
| Aaron Bloomer | EXAS | Common Stock | Options Exercise | 63,099 | 59,571 | 23 Dec 2025 | Direct | |||
| Aaron Bloomer | EXAS | Restricted Stock Units | Options Exercise | -100% | -63,099 | 0 | 23 Dec 2025 | Direct | ||
| Jacob A. Orville | EXAS | Common Stock | Sale | -17.7% | $375,000 | $75.00 | -5,000 | 23,237 | 19 Nov 2025 | Direct |
| James Herriott | EXAS | Common Stock | Sale | -7.95% | $70,000 | $70.00 | -1,000 | 11,585 | 19 Nov 2025 | Direct |
| James Herriott | EXAS | Common Stock | Sale | -10.6% | $105,120 | $70.08 | -1,500 | 12,585 | 04 Nov 2025 | Direct |
| Brian Baranick | EXAS | Common Stock | Sale | -11.3% | $200,289 | $70.08 | -2,858 | 22,368 | 04 Nov 2025 | Direct |
| Katherine S. Zanotti | EXAS | Common Stock | Sale | -16.5% | $780,000 | $65.00 | -12,000 | 60,759 | 24 Oct 2025 | Direct |
| James Herriott | EXAS | Common Stock | Sale | -9.62% | $90,000 | $60.00 | -1,500 | 14,085 | 09 Oct 2025 | Direct |
| James Edward Doyle | EXAS | Common Stock | Sale | -3.34% | $120,000 | $60.00 | -2,000 | 57,962 | 09 Oct 2025 | Direct |
| James Edward Doyle | EXAS | Common Stock | Sale | -2.42% | $62,400 | $42.02 | -1,485 | 59,962 | 13 Aug 2025 | Direct |
| Jacob A. Orville | EXAS | Common Stock | Tax liability | -8.18% | -2,515 | 28,237 | 05 Aug 2025 | Direct | ||
| Jacob A. Orville | EXAS | Common Stock | Options Exercise | 21.1% | 5,350 | 30,752 | 05 Aug 2025 | Direct | ||
| Jacob A. Orville | EXAS | Restricted Stock Units | Options Exercise | -25% | -5,350 | 16,051 | 05 Aug 2025 | Direct | ||
| Brian Baranick | EXAS | Common Stock | Tax liability | -9.72% | -2,717 | 25,226 | 05 Aug 2025 | Direct | ||
| Brian Baranick | EXAS | Common Stock | Options Exercise | 23.7% | 5,350 | 27,943 | 05 Aug 2025 | Direct |